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Enhanced interleukin-1b production of PBMCs
from patients with gout after stimulation with
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Abstract
Introduction: Monosodium urate monohydrate (MSU) crystals synergize with various toll-like receptor (TLR) ligands
to induce cytokine production via activation of the NOD-like receptor (NLR) family, pyrin domain-containing
3 (NLPR3) inflammasome. This has been demonstrated in vitro using human cell lines or monocytes of healthy
volunteers. In the present study, we have investigated the effect of MSU crystals and of their combination with TLR
ligands in peripheral blood mononuclear cells (PBMC) of patients with gout.
Methods: PBMCs from 18 patients with primary gout and 12 healthy donors were exposed to MSU crystals in the
presence or absence of saturated fatty acid C18:0 (free fatty acid, TLR2 ligand), palmitoyl-3-cystein (Pam3Cys, TLR1/2
ligand) and fibroblast stimulating factor-1 (FSL-1, TLR 2/6 ligand). Production of IL-1b, IL-6, IL-8, IL-17 and tumor
necrosis factor alpha (TNFa) was determined by ELISA. mRNA transcripts of IL-1b were measured by real-time PCR.
Results: MSU crystals alone failed to induce IL-1b, IL-6 or TNFa in both patients and control groups, but a stronger
synergy between MSU/Pam3Cys and MSU/C18:0 for the induction of IL-1b was found in patients with gout
compared to healthy controls. IL-6, but not IL-8, followed the kinetics of IL-1b. No production of the neutrophil-
recruiting IL-17 was detectable after stimulation of the patients’ PBMCs with MSU in both the presence or absence of
TLR ligands. No change of gene transcripts of IL-1b after stimulation with MSU and Pam3Cys or with MSU and C18:0
was found. A positive correlation was found between synergy in IL-1b production from PBMCs of patients between
C18:0 and MSU crystals, as well as the annual number of attacks of acute gouty arthritis (rs: +0.649, P: 0.022).
Conclusions: The synergy between MSU crystals and TLR-2 ligands is more prominent in patients with gout than
in controls. This is likely mediated by the enhanced maturation of pro-IL-1b into IL-1b.
Introduction
Gout is a crystal-induced inflammatory disease induced
by the deposition of crystals of monosodium urate mono-
hydrate (MSU) in the joints and in the synovial mem-
branes [1]. The arthritis is mediated by pro-inflammatory
cytokines, produced by activated innate immune cells [2].
Among these cytokines, IL-1b seems to play a pivotal
role [3]. This was proven in clinical studies, in which
selective blockade of IL-1b effectively suppressed pain
and inflammation in patients with gout that was refrac-
tory to other treatments [4-6].
Synthesis of bioactive IL-1b is induced in two steps: in
the first step, gene expression leads to synthesis of inactive
pro-IL-1b; in the second step, pro-IL-1b is cleaved by the
protease caspase-1 to yield mature IL-1b [7]. For activation
of caspase-1, intracellular molecular platforms called
inflammasomes have to be assembled [8]. MSU crystals
have been reported to activate the MOD-like receptor
(NLR) family, pyrin domain-containing 3 (NLPR3) inflam-
masome and induce IL-1b production via caspase-1-
dependent processing [9,10]. However, purified MSU
crystals induce moderate amounts of IL-1b by themselves
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[11,12]; they require co-stimulation with toll-like receptor
(TLR) ligands such as lipopolysaccharide (LPS) [11] or free
fatty acids (FFA) [12].
This necessity of co-stimulation is in agreement with
the clinical wisdom that, in the context of chronically
elevated uric acid concentrations, attacks of gout are
preceded by infections or excess intake of alcohol or
dietary fat.
The in vitro studies performed until now have either
studied human monocyte cell lines [9] or primary
mononuclear cells of healthy volunteers [9,11,12] but
the IL-1b production capacity of primary cells of
patients with gout has not been investigated. In this
study, we investigated whether primary cells [peripheral
blood mononuclear cells (PBMCs)] of patients with gout
also need this dual stimulation for cytokine production.
The role of IL-1b stimulation in gout was investigated
in an effort to decipher if the pathophysiological phe-
nomena of attacks of acute gouty arthritis are related to
the excess production of IL-1b or of other cytokines
mediating chemotaxis of neutrophils at the inflamed
synovium, namely IL-18 and IL-17.
Materials and methods
Patients
Eighteen patients with gout (13 men, five women, aged
63.5 ± 13.6 years, Table 1) and 12 healthy volunteers
(6 men, 6 women, aged 41.17 ± 14.41 years) were asked
to donate blood. The study protocol received approval
from the Ethics Committee of ATTIKON University
Hospital. Patients were enrolled after written informed
consent. Inclusion criteria were: a) diagnosis of primary
gout; b) history of at least two acute gouty attacks; and
c) blood sampling in interictal periods. Patients taking
any anti-inflammatory medication in the previous
15 days were excluded from the study. Primary gout
and an acute attack of gout were defined according to
the criteria outlined by the American Rheumatism Asso-
ciation [13]. After informed consent, 30 ml of venous
blood was collected under sterile conditions.
Preparation of monosodium urate monohydrate (MSU)
crystals and of ultrapure C18:0
MSU crystals were prepared according to the method
described by Seegmiller et al. [14]. Briefly, a solution of
0.03 M of MSU at a volume of 200 ml was prepared after
diluting 1.0 g of uric acid (Sigma Co, St Louis, MO, USA)
in 200 ml of sterile water containing 24 g of NaOH. The
pH was adjusted to 7.2 after addition of HCl and the
solution became pyrogen-free after incubation for six
hours at 120°C. Concentrations of LPS were below 0.01
ng/ml as measured by the kinetic LAL QCL-1000 assay
(BioWhittaker-Walkersville, Maryland. USA). The solu-
tion was left to cool at room temperature and stored at
4°C. Produced crystals were 5 to 25 μm long (Figure 1).
On each day of the experiment, a small amount of crys-
tals was weighted under sterile conditions for application.
A 200 mM stock solution of ultrapure C18:0 fatty
acids (Sigma Co) at a volume of 5 ml ethanol 100% was
prepared. The stock was warmed at 37°C in a water
Table 1 Clinical characteristics of 18 patients with gout enrolled in the study.
No Age (years) Co-morbidities Number of affected joints Number of annual attacks Therapy of attacks
1 75 DM2, VH, COPD 2 2 Colchicine
2 80 DM2, VH, CHD 4 5 Colchicine
3 62 DM2, VH, obesity 1 1 Colchicine
4 80 DM2, COPD, CHD 1 1 Colchicine
5 45 VH, obesity 1 1 Colchicine
6 70 VH 1 1 Colchicine
7 67 DM2, VH, CHD 7 5 NSAIDs
8 65 VH, obesity 1 1 Colchicine
9 62 VH 1 1 Colchicine
10 55 VH, obesity 2 1 Colchicine
11 80 DM2, VH 2 2 NSAIDs
12 32 Obesity 4 6 NSAIDs
13 70 VH 1 1 Colchicine
14 70 DM2, VH 3 2 Colchicine
15 68 Obesity 1 3 Colchicine
16 52 DM2, CRD 1 10 Colchicine
17 69 CRD 5 4 Colchicine
18 46 CRD 1 5 Colchicine
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CRD, chronic renal disease; DM2, diabetes mellitus type 2; NSAIDs, non-steroidal anti-
inflammatory drugs; VH, vascular hypertension.
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bath and pre-diluted to 20 mM with ethanol 100%,
before use. A concentration of 200 μM C18:0 was used
to stimulate PBMCs and the final concentration of etha-
nol in the wells of a 96-well plate was 0.55 %. Although
this concentration appears high, it is consistent with the
concentrations that exist in the joint as reflected indir-
ectly by the circulating concentrations of free fatty acids
of patients before and after total hip arthroplasty [15].
Stimulation of cytokine production
PBMCs were isolated after gradient centrifugation of
heparinized whole blood over FicolHypaque (Biochrom,
Berlin, Germany). After three consecutive washings in
ice-cold PBS pH 7.2 (Biochrom), PBMCs were counted
in a Neubauer chamber after trypan blue exclusion of
dead cells. They were then distributed into wells of a
96-well plate at a final concentration of 2 × 106/ml in
RPMI 1640 (Biochrom) enriched with 2 mM glutamine
(Biochrom), 10 μg/ml of gentamicin and 100 U/ml of
penicillin G. PBMCs were stimulated with 200 μg/ml of
highly purified MSU, with 200 μΜ of ultrapure fatty acid
[C18:0] which is a TLR2 ligand, with 10 μg/ml of the
TLR1/2 ligand palmitoyl-3-cystein [Pam3Cys- SKKKK]
(EMC MicrocollectionsGmbH, Tübingen, Germany) and
with 1 μg/ml of the TLR2/6 ligand fibroblast stimulating
ligand-1 [FSL-1] (EMC MicrocollectionsGmbH). Pam3-
CysandFSL-1 stock solutions in distilled water were used.
All experiments were run in duplicate with cells of
at least one healthy donor per day of experiment. After
24 hours of incubation, plates were centrifuged and
supernatants were collected and stored at -80°C until the
cytokine assays were performed. For assessment of IL-17
production, the culture period was five days with fetal
bovine serum (FBS) added to the culture medium at a
final concentration of 10%.
PBMCs used for this analysis consist of lymphocytes
and monocytes in an almost 3:1 ratio. Ideally, to measure
cytokines released from the monocyte fraction of PBMCs,
further monocyte separation should be performed. This
generates some danger for ex vivo stimulation of mono-
cytes by the separation media providing erroneous false-
positive results. However, stimulation of PBMCs for
24 hours provides cytokines coming from the monocyte
fraction as already considered in previous publications of
our group [16].
Cytokine measurement
Human TNFa, IL-1b, IL-6, IL-8 and IL-17 in supernatants
were measured by ELISA (R&D systems, Minneapolis,
MN, USA) according to the instructions of the manufac-
turer. The lowest limits of detection were 40 pg/ml for
TNFa, 20 pg/ml for IL-1b, 16 pg/ml for IL-6, 165 pg/ml
for IL-8, and 80 pg/ml for IL-17.
Quantitative PCR for mRNA expression of IL-1b
PBMCs were cultured with the stimuli as mentioned
above and after four hours of incubation at 37°C in 5%
CO2 the plates were centrifuged, the cell pellets were lysed
Figure 1 Polarized microscopy of the prepared crystals of monosodium urate.
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with 400 μl of Trizol (AppliChem GmbH, Darmstadt, Ger-
many) and kept at -80°C until extraction of RNA.
RNA was extracted with chloroform and gradient centri-
fugation for 15 minutes at 4°C and 12,000 g followed by
treatment for 30 minutes at 37°C with 0.04 U/μl of
DNAase (New England BioLabs, Ipswich, MA, USA).
RNA was detected after 3% agarose gel electrophoresis
and ethidium bromide staining. A total of 1.5 μg of RNA
(Pharmacia Biotech photometer) was used for the produc-
tion of cDNA using 0.4 mM of dNTPs (New England Bio-
Labs), 1 U of RNA-sin (New England BioLabs), 10 mM
dithiothreitol (DTT) (AppliChem GmbH) and 5x of the
reverse transcriptase buffer in a Sensoquest thermal cycler
LabCycler Gradient using appropriate blanks (Eppedorf,
Hamburg, Germay). After an initial incubation step of
10 minutes at 60°C, 1 μU of reverse transcriptase (New
England BioLabs) was added followed by three cycles:
10 minutes at 25°C, 50 minutes at 42°C and 15 minutes at
70°C. cDNA was kept at -80°C until assayed
Expression of mRNA was tested by the iCycler system
(BioRad, Philadelphia, PA, USA) using 1μl of cDNA,
0.1 mg/ml of sense and antisense primers, 3mM of
MgCl2 (New England BioLabs), 0.25 mM of dNTPs
(New England BioLabs), 10x buffer and 1 mM of Taq
polymerase with SYBR-Gr as a fluorochrome in each
tube. Primer sequences were: for IL-1b sense 5’- CAG
CTA CGA ATC TCC GAC CAC-3’ and antisense 5’-
GGC AGG GAA CCA GCA TCT TC-3’, and for b2-
microglobulin sense 5’-ATG AGT ATG CCT GCC
GTG TG-3’ and antisense 5’-CCA AAT GCG GCA
TCT TCA AAC-3’. After an initial denaturation step for
10 minutes at 95°C, 34 cycles were performed. Each
cycle consisted of: denaturation for 30 seconds at 95°C,
annealing for 30 seconds at 72°C and elongation for
30 seconds at 95°C. Amplification was followed by a
melting curve, appropriate blanks were applied. The
PCR product was identified after 3% agarose gel electro-
phoresis and ethidium bromide staining. Quantitative
results were expressed as defined by the Pfaffl equation
[17], using the efficiency of a standard curve created
with known cDNA.
Statistical analysis
Data on cytokines are expressed as medians ± 95%
confidence intervals (CI); those of gene transcripts by
their mean ± SE. Comparisons between groups were
done using the Mann-Whitney U test. Folds of change
of cytokine production after treatment with a combina-
tion of stimuli compared with the most active single
stimulus were calculated; comparisons between
patients and healthy volunteers were done by the
Mann-Whitney U test. Any more than a 30% increase
was considered as significant synergy. Comparison
between groups was done by the Fischer’s exact test.
Correlations between folds of changes of cytokine pro-
duction and of the annual number of attacks of acute
gouty arthritis of patients were determined according
to Spearman. P values less than 0.05 were considered
significant.
Results
Cytokine production after exposure to MSU and TLR
ligands
We stimulated PBMCs of patients with gout and of healthy
donors with either the TLR2/6 ligand FSL-1 or TLR1/2
ligand Pam3Cys (Figure 2). We found that production of
IL-1b did not significantly differ between patients and con-
trols, although IL-1b production in cells of gout patients
showed a wide variation and a tendency to higher produc-
tion when exposed to Pam3Cys (Figure 2A).
Exposure of PBMCs to ultrapure MSU crystals did not
induce IL-1b production in either of the two groups
(Figure 3A). Co-incubation of MSU with FSL-1 did not
change the release of cytokines achieved by single FSL-1
(Figure 3). When PBMCs of gout patients were incubated
with MSU crystals together with Pam3Cys, production of
IL-1b was significantly increased compared to Pam3Cys
alone (Figure 4). IL-6, IL-8 or TNFa released by PBMCs
was not significantly different between gout patients and
controls for any of the stimuli, single or in combination
(Figures 2, 3 and 4).
Cytokine induction by MSU and saturated fatty acids
Recently, we demonstrated that the addition of C18:0
fatty acid augments IL-1b production of PBMCs
exposed to MSU [12]. In the present study, we show
that PBMCs from gout patients produce more IL-1b
than controls when incubated with C18:0 and MSU
(Figure 5A). However, we noted that exposure of
PBMCs to C18.0 alone also stimulated IL-1b produc-
tion, most likely due to a different preparation of C18.0
stimuli than in previous studies (containing a low final
concentration of 0.55% ethanol). The production of IL-6
by MSU/C18:0 was in line with IL-1b production in
cells isolated from gout patients, with a trend towards
higher cytokine production in gout patients than in
healthy controls. Release of TNFa and of IL-8 after co-
stimulation with C18:0 and MSU did not differ between
patients and healthy controls.
Undoubtedly, the wide variation in cytokine production
raises questions about the robustness of the finding. In
order to make the result robust four types of analysis
were performed: a) statistical comparisons reported in
Figures 5A and 5B were performed using non-parametric
tests; b) qualitative analysis disclosed that synergy of FFA
C18:0 with MSU crystals for the production of IL-1b and
IL-6 was found in 15 of 18 patients versus 2 of 12 con-
trols, P = 0.001); c) fold-changes of IL-1b and of IL-6
Mylona et al. Arthritis Research & Therapy 2012, 14:R158
http://arthritis-research.com/content/14/4/R158
Page 4 of 10
production after stimulation of PBMCs of patients with
the combination of C18:0 and MSU crystals compared to
C18:0 alone were significantly greater compared to
respective changes of healthy controls (Figure 6); and d)
a positive correlation was found between the change of
IL-1b production after stimulation of PBMCs of patients
with the combination of C18:0 and MSU crystals com-
pared to C18:0 alone and the annual number of attacks
of acute gouty arthritis of these patients (P = 0.022,
Figure 7). Significant correlations were not found
between changes of IL-1b by the combination of
Pam3Cys and MSU compared to Pam3Cys alone and the
annual number of attacks of acute gouty arthritis (data
not shown, rs: +0.596, P = 0289).
To exclude the possibility that part of the explanation
for the synergy between C18:0 and MSU is due to the
younger age of healthy controls, correlation analysis was
done between the age of both healthy donors and patients
and the fold change of IL-1b production by the
combination compared with C18:0 alone. No statistically
significant results were found (rs: +0.170, P = 0.428).
Lack of IL-17 production by PBMCs after MSU and TLR2
ligands
A hallmark of acute gout is the influx of neutrophils
into the synovium and joint fluid [18]. In order to define
over-production in IL-1b release as the major culprit for
attacks of gout, production of other cytokines mediating
chemotaxis of neutrophils, notably IL-8 and IL-17,
should not be affected by co-incubation with C18:0 and
MSU. The cytokine IL-17 induces neutrophil-attracting
chemokines and granulopoietic cytokines, and recruits
neutrophils to the site of inflammation [19]. PBMCs of
both gout patients and healthy controls exhibited no
detectable production of IL-17 after stimulation with
MSU crystals for five days, either in the presence or
absence of FSL-1, Pam3Cys or C18:0 fatty acids (data
not shown).
Figure 2 PBMCs from gout patients produce more IL-1band IL-6 compared to healthy controls when exposed to TLR ligands. Release
of IL-1b(A), IL-6 (B), IL-8 (C) and TNFa (D) by PBMCs of patients with gout and healthy donors after their stimulation with growth medium
(RPMI), palmitoyl-3-cystein [Pam3Cys] (TLR2/1 agonist) or fibroblast stimulation ligand-1 [FLS-1] (TLR2/6 ligand). Asterisks denote outliers and
circles denote extremes. Gout patients n = 18 and healthy controls n = 12. PBMC, peripheral blood mononuclear cells; TLR, toll-like receptor.
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Effect on gene transcription
The synergy between TLR-2 ligands and MSU crystals
might lead either to enhanced expression of the IL-1b
gene or to increased cleavage of pro-IL-1b by caspase-1.
mRNA transcripts of IL-1b in the PBMCs of gout
patients did not have any difference after addition of
MSU crystals to FFA C18:0, compared with healthy
donors (Figure 8A). Similar findings were observed after
stimulation with MSU and Pam3Cys (Figure 8B).
Discussion
In the present paper, we report that PBMCs of gout
patients who have experienced attacks of arthritis pro-
duce more IL-1b than PBMCs of healthy volunteers
when the cells are exposed to a combination of TLR2
ligands and MSU crystals. In addition, the IL-1b response
in the presence of C18:0 fatty acids together with MSU is
augmented in the majority of the gout patients.
The responses in the gout patients show a much wider
variation than those in healthy volunteers. These varia-
tions may be partly explained by the variations of the
annual attacks of acute gouty arthritis in the patient
group since synergy for IL-1b production is pronounced
for patients with frequent attacks of acute gouty arthri-
tis. We found that the synergism between MSU and
FFA C18:0 leading to production of IL-1b is not due to
enhanced gene expression. The most likely explanation
is increased cleavage of pro-IL-1b to IL-1b in patients
with gout. Enhanced cleavage may be mediated through
the NLRP3 inflammasome, since MSU is one agonist for
the NLRP3 inflammasome. Our finding that this synergy
was also present for IL-6 (which is at least in part
induced by endogenous bioactive IL-1) underscored the
activation of the inflammasome. However, it should not
be neglected that other proteinases, namely, neutrophil
elastase and cathepsin G, may mediate cleavage of pro-
Figure 3 Lack of synergy between MSU and FSL-1 in the induction of IL-1b. Release of IL-1b (A), IL-6 (B) IL-8 (C) and TNFa (D)by peripheral
blood mononuclear cells of patients with gout and healthy donors after having been left untreated (RPMI) or stimulated by monosodium urate
monohydrate (MSU) crystals alone or in combination with fibroblast stimulation ligand-1 [FLS-1]. Asterisks denote outliers and circles denote
extremes. P values indicate significant differences between respective values of patients and healthy controls by Mann-Whitney U-test. Gout
patients n = 18 and healthy controls n = 12.
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IL-1b to IL-1b [20] but this is unlikely in the present
study since they are present at very low levels in the
PBMC preparations.
Our findings suggest that the NLRP3 inflammasome
may be activated more readily in patients with gout
than in healthy controls. The synergistic effects for the
production of IL-1b were mainly found between MSU
and Pam3Cys and between MSU and FFA C18:0, but
not between MSU and FSL-1, providing evidence that
MSU synergizes with TLR2/1 agonists but not with
TLR2/6.
Several groups have shown that MSU crystals function
as inflammasome activators [9-11]. Initial reports sug-
gested that urate crystals were able to induce IL-1b on
their own. When we reported that MSU crystals need
the presence of a second stimulus such as LPS [11] or
FFA C18:0 [12], it turned out that others had also used
LPS as an inducer of pro-IL-1b transcripts [13]. This
would fit with everyday clinical practice: while hyperuri-
cemia is a prerequisite for gout, its presence does not
always lead to disease and a second stimulus such as
infection, excessive alcohol intake or a fatty meal is
needed for an attack to occur. The data in the literature
on IL-1b production in gout were obtained by the use
of either primary mononuclear cells of healthy volun-
teers [9,11,12] or human monocytic cell lines (THP-1)
cells [10]; this is the first study using cells of gout
patients.
The infiltration of the synovium by neutrophils is con-
sidered to be a feature of the acute inflammation in gout
[1]. The recent literature indicates that IL-17 is a potent
mediator of neutrophil influx, by expansion of the neu-
trophil lineage through induction of Granulocye-colony
stimulating factor (G-CSF) as well as by recruitment of
neutrophils through the induction of chemokines [19].
IL-17 is mainly released by a distinct subset of T helper
Figure 4 Synergy between MSU and Pam3Cys in the induction of IL-1b was greater in patients than controls. Release of IL-1b (A), IL-6
(B), IL-8 (C) and TNFa (D) by peripheral blood mononuclear cells of patients with gout and healthy donors after having been left untreated
(RPMI) or stimulated by monosodium urate monohydrate (MSU) crystals alone or in combination with palmitoyl-3-cystein [Pam3Cys]. Asterisks
denote outliers and circles denote extremes. P values indicate significant differences between respective values of patients and healthy controls
by Mann-Whitney U-test. Gout patients n = 18 and healthy controls n = 12.
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Figure 5 Patients displayed greater synergy between MSU and C18:0 in the induction of IL-1b than healthy donors. Release of IL-1b (A),
IL-6 (B), IL-8 (C) and TNFa (D)by peripheral blood mononuclear cells of patients with gout and healthy volunteers after stimulation with medium
alone (RPMI), monosodium urate monohydrate (MSU) crystals and saturated fatty acids C18:0 alone or in combination with MSU. Asterisks
denote outliers and circles denote extremes. P values indicate significant differences between respective values of patients and healthy controls
by Mann-Whitney U test. Gout patients n = 18 and healthy controls n = 12.
Figure 6 Changes of production of cytokines from PBMCs of
gout patients and of healthy volunteers after stimulation with
FFA C18:0 and MSU. x fold refers to changes compared with the
most active single stimulus. P values indicate significant differences
between respective values of patients and healthy controls by
Mann-Whitney U-test. Gout patients n = 18 and healthy controls n
= 12. FFA, free fatty acids; MSU, monosodium urate monohydrate;
PBMC, peripheral blood mononuclear cells.
Figure 7 Correlation between synergy for IL-1b production and
the annual number of attacks of acute gouty arthritis. The x
fold change of IL-1b produced by the combination of free fatty
acids C18:0 and monosodium urate (MSU) compared with C18:0
alone is shown.
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cells, called Th17, which derive from the naïve CD4+
T-cells [21]. We measured IL-17 in order to find out
whether acute gouty inflammation is under the control of
IL-17. The lack of production of IL-17, observed in the
present study, supports the view that neutrophil influx in
gouty inflammation is probably due to the release of
other neutrophil-recruiting cytokines, such as IL-1b. In
fact, Th17 cells are generated after days and this is not
compatible with the rapid occurrence of inflammation in
gout.
Despite our inability to find a direct relationship
between uric acid concentrations in serum and the
degree to which the inflammasome is activated, hyperuri-
cemia still may be the explanation for the increased acti-
vation of the inflammasome in patients with gout. At the
molecular level uric acid, in its soluble form, has been
reported to have a role in regulating redox homeostasis
by forming radicals in reaction with other oxidants [22].
Moreover, it has been suggested that reactive oxygen spe-
cies (ROS) may activate the NLRP3 inflammasome [23].
However, based on the findings of a previous study by
our group, ROS are not involved in inflammasome acti-
vation, since PBMCs from ROS deficient patients pro-
duce significantly more IL-1b after exposure to MSU
crystals than the cells from healthy individuals [24].
Our findings were generated with circulating PBMCs of
patients. As such, it may be speculated that the over-
inflammatory state produced in gout is systemic and not
limited to joints. This speculation is consistent with the
wide variation of co-morbidities recognized in these
patients [1].
Conclusions
The present study provides evidence that the PBMCs of
patients with gout display a more prominent synergistic
production of IL-1b after stimulation with MSU crystals
and TLR-2/1 ligands, compared to healthy controls.
This synergy may be mediated by enhanced maturation
of pro-IL-1b into IL-1b.
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